Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07600697 · ClinicalTrials.gov registry record · Phase 4
Suzetrigine for Opioid-Sparing Postoperative Analgesia Following Transvaginal Pelvic Reconstructive Surgery
A Phase 4 study, sponsored by University of California, Los Angeles.
- Not yet
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
NCT07600697 is a Phase 4 study that has not yet begun recruiting, run by University of California, Los Angeles. The registered enrollment target is 120 participants.
The verdict
NCT07600697, a Phase 4 study, has not yet begun recruiting, sponsored by University of California, Los Angeles.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
Study Summary
Suzetrigine is a selective NaV1.8 inhibitor that provides peripheral analgesia without opioid-related CNS effects. This single-center stepped-wedge randomized clinical trial evaluates whether a suzetrigine-based postoperative analgesic regimen provides non-inferior pain control compared with standard opioid-inclusive care following transvaginal pelvic reconstructive surgery. The study will enroll 120 participants and assess pain, opioid consumption, adverse events, and functional recovery.
Interventions
- DRUG Suzetrigine
- DRUG Opioid Analgesics (Tramadol or Oxycodone)
- DRUG Scheduled Acetaminophen and Ibuprofen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2028-07-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07600697
The ClinicalTrials.gov registry entry for NCT07600697 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Suzetrigine is the first listed.
NCT07600697 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07600697 about?
NCT07600697 is a clinical study titled "Suzetrigine for Opioid-Sparing Postoperative Analgesia Following Transvaginal Pelvic Reconstructive Surgery". Suzetrigine is a selective NaV1.8 inhibitor that provides peripheral analgesia without opioid-related CNS effects. This single-center stepped-wedge randomized clinical trial evaluates whether a suzetrigine-based postoperative analgesic regimen provides non-inferior pain control compared with standar...
What is the current status of trial NCT07600697?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2026-07-01. Estimated completion is 2028-07-01.
What interventions are being tested in trial NCT07600697?
The interventions under investigation include: Suzetrigine (DRUG), Opioid Analgesics (Tramadol or Oxycodone) (DRUG), Scheduled Acetaminophen and Ibuprofen (DRUG).
Who is sponsoring clinical trial NCT07600697?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.